

TRALI - Was lange währt, wird endlich gut Eine Erfolgsgeschichte in der Transfusionsmedizin

- 1) *Serious Hazards of Transfusion (SHOT).*
Additional cumulative data 1996-2003. und SHOT Report 2004. www.shotuk.org.
- 2) Sazama K:
Reports of 355 transfusion-associated deaths: 1976 through 1985.
Transfusion 1990;**30**:583-90.
- 3) Barnard RD.
Indiscriminate transfusion: a critique of case reports illustrating hypersensitivity reactions.
NY State J Med 1951;**51**:2399-2402.
- 4) Brittingham TE.
Immunologic studies on leukocytes.
Vox Sang 1957;**2**:242-48.
- 5) Ward HN.
Pulmonary infiltrates associated with leukoagglutinin transfusion reactions.
Ann Intern Med. 1970;**73**:689-94.
- 6) Thompson JS, Severson CD, Parmely MJ, Marmorstein BL, Simmons A.
Pulmonary "hypersensitivity" reactions induced by transfusion of non-HL-A leukoagglutinins.
N Engl J Med. 1971;**284**:1120-5.
- 7) Popovsky MA, Abel MP, Moore SB:
Transfusion-related acute lung injury associated with passive transfer of antileukocyte antibodies.
Am Rev Respir Dis 1983;**128**:185-89.
- 8) Popovsky MA, Moore SB.
Diagnostic and pathogenetic considerations in transfusion-related acute lung injury.
Transfusion 1985;**25**:573-77.
- 9) Kopko PM, Popovsky MA, MacKenzie MR, Paglieroni TG, Muto KN, Holland PV.
HLA class II antibodies in transfusion-related acute lung injury.
Transfusion 2001;**41**:1244-8.
- 10) Kopko PM, Paglieroni TG, Popovsky MA, Muto KN, MacKenzie MR, Holland PV.
TRALI: correlation of antigen-antibody and monocyte activation in donor-recipient pairs.
Transfusion. 2003;**43**(2):177-184.
- 11) Nishimura M, Hashimoto S, Takanashi M, Okazaki H, Satake M, Nakajima K.
Role of antihuman leucocyte antigen class II alloantibody and monocytes in development of transfusionrelated acute lung injury.
Transfus Med. 2007;**17**(2):129-134.
- 12) Sachs UJ, Wasel W, Bayat B, Bohle RM, Hattar K, Berghöfer H, Reil A, Bux J, Bein G, Santoso S., Weissmann N.
Mechanism of transfusion-related acute lung injury induced by HLA class II antibodies.
Blood. 2011;**117**:669-77.
- 13) Silliman CC, Paterson AJ, Dickey WO, Stroncek DF, Popovsky MA, Caldwell SA, Ambruso DR.
The association of biologically active lipids with the development of transfusion-related acute lung injury: a retrospective study.
Transfusion 1997;**37**:719-26.
- 14) Silliman CC, Boshkov LK, Mehdizadehkashi Z, Elzi DJ, Dickey WO, Podlosky L, Clarke G, Ambruso DR.
Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors.
Blood 2003;**101**:454-62

- 15) European Haemovigilance Network (EHN).
Definitions of Adverse Transfusion Events.
www.ehn-org.net.
- 16) Kleinman S, Caulfield T, Chan P, Davenport R, McFarland J, McPhedran S, Meade M, Morrison D, Pinsent T, Robillard P, Slinger P.
Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel.
Transfusion 2004;**44**:1774-89.
- 17) Doerschuk CM.
Neutrophil rheology and transit through capillaries and sinusoids.
Am J Respir Crit Care Med 1999;**59**:1693-1695.
- 18) Sachs UJH, Hattar K, Weissmann N, Bohle RM, Weiss T, Sibelius U, Bux J.
Antibody-induced neutrophil activation as a trigger for transfusions-related acute lung injury in an ex-vivo rat lung model.
Blood 2006;**107**:1217-1219.
- 19) Seeger W, Schneider U, Kreusler B, Witzleben EV, Walmrath D, Grimminger F, Neppert J
Reproduction of transfusion-related acute lung injury in an ex vivo lung model.
Blood 1990;**76**:1438-1444.
- 20) Graul A, Heiden M, Gräf K, Keller-Stanislawski B.
Hämovigilanz in Deutschland – Berichte an das Paul-Ehrlich-Institut über Verdachtsfälle von Transfusionsreaktionen im Beobachtungszeitraum Januar 1995 – Dezember 2002.
Transfus Med Hemother 2003;**30**:232-38.
- 21) Keller-Stanislawski B, Reil A, Günay S, Funk MB.
Frequency and severity of transfusion-related acute lung injury – German haemovigilance data (2006–2007).
Vox Sang 2009; **98**:70-7.
- 22) Reil A., Keller-Stanislawski B., Günay S., Bux J.
Specificities of leucocyte alloantibodies in transfusion-related acute lung injury and results of leucocyte antibody screening of blood donors.
Vox Sang 2008;**95**:313-17.
- 23) Nordhagen R, Conradi M, Drötorp SM.
Pulmonary reaction associated with transfusion of plasma containing anti-5b.
Vox Sang 1986;**51**:102-7.
- 24) Votum 39 des Arbeitskreises Blut (01.2009)
Maßnahmen zur Vermeidung der transfusionsinduzierten Lungeninsuffizienz (TRALI).
www.rki.de/DE/Content/Kommissionen/AK_Blut/Voten/voten_node.html.
- 25) Bekanntmachung über die Zulassung von Arzneimitteln - Abwehr von Arzneimittelrisiken - Anordnung von Auflagen zu den Zulassungen von therapeutischem Einzelplasma (in Quarantäne gelagertes oder mit einem Verfahren zur Pathogeninaktivierung behandeltes Plasma) (vom 08. Mai 2009)
Bundesanzeiger Nr. 84 vom 10.06.2009, Seite 2064.
- 26) van Leeuwen, A, Eernisse, JG, van Rood JJ.
A new leucocyte group with two alleles: Leucocyte group five.
Vox Sang 1964;**9**:431-46.
- 27) Greinacher A, Wesche J, Hammer E, Füll B, Völker U, Reil A, Bux J.
Characterization of the human neutrophil alloantigen-3a.
Nat Med. 2010;**16**:45-8

- 28) Berthold T, Wesche J, Kuhnert K, Füll B, Hippe H, Hoppen J., Reil A, Muschter S, Bux J, Greinacher A.
Epitope mapping of antibodies directed against the human neutrophil alloantigen 3a.
Transfusion 2011;**51**:2160-7.
- 29) Reil A, Wesche J, Greinacher A, Bux J.
Geno- and phenotyping and immunogenicity of HNA-3.
Transfusion 2011;**51**:18-24.
- 30) Stroncek, DF, Clay M.
Is it time to reconsider neutrophil antibody testing of platelet donors?
Transfusion 2011;**51**:2-4.
- 31) Funk MB, Guenay S, Lohmann A, Henseler O, Keller-Stanislawski B.
Bewertung der Maßnahmen zur Reduktion schwerwiegender Transfusionsreaktionen (Hämovigilanzdaten von 1997 bis 2008).
Bundesgesundheitsbl 2010;**53**:347-56.
- 32) Funk MB, Guenay S, Lohmann A, Henseler O, Heiden M, Hanschmann KM, Keller-Stanislawski B.
Benefit of transfusion-related acute lung injury risk-minimization measures - German haemovigilance data (2006-2010).
Vox Sang 2012;**102**:317-23.
- 33) Bux, J.
Die transfusionsassoziierte akute Lungeninsuffizienz (TRALI) - eine gefährliche, aber wenig bekannte Transfusionsreaktion.
hämotherapie 2005;**05**:4-11.